Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): A phase 3b study in refractory multiple myeloma


Dimopoulos MA, Palumbo A, Corradini P, Cavo M, Delforge M, Di Raimondo F, Weisel KC, Oriol A, Hansson M, Vacca A, et al. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): A phase 3b study in refractory multiple myeloma. Blood [Internet]. 2016;128(4):497 - 503.


Patients with relapsed and/or refractory multiple myeloma (RRMM) have poor prognosis. The STRATUS study assessed safety and efficacy of pomalidomide plus low-dose dexamethasone in the largest cohort to date of patients with RRMM. Patients who failed treatment with bortezomib and lenalidomide and had adequate prior alkylator therapy were eligible. Pomalidomide 4 mg was given on days 1-21 of 28-day cycles with low-dose dexamethasone 40 mg (20 mg for patients aged >75 years) on days 1, 8, 15, and 22 until progressive disease or unacceptable toxicity. Safety was the primary end point; secondary end points included overall response rate (ORR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS). Among 682 patients enrolled, median age was 66 years, and median time since diagnosis was 5.3 years. Median number of prior regimens was 5. Most patients were refractory to both lenalidomide and bortezomib (80.2%). Median follow-up was 16.8 months; median duration of treatment was 4.9 months. Most frequent grade 3/4 treatment-emergent adverse events were hematologic (neutropenia [49.7%], anemia [33.0%], and thrombocytopenia [24.1%]). Most common grade 3/4 nonhematologic toxicities were pneumonia (10.9%) and fatigue (5.9%). Grade 3/4 venous thromboembolism and peripheral neuropathy were rare (1.6% each). The ORR was 32.6%, and the median DOR was 7.4 months. Median PFS and OS were 4.6 months and 11.9 months, respectively. We present the largest trial to date evaluating pomalidomide plus low-dose dexamethasone in patients with RRMM, further confirming that this regimen offers clinically meaningful benefit and is generally well tolerated. identifier NCT01712789. © 2016 by The American Society of Hematology.


Cited By :8Export Date: 18 February 2017References: Kumar, S.K., Lee, J.H., Lahuerta, J.J., Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study (2012) Leukemia, 26 (1), pp. 149-157. , published correction appears in Leukemia. 2012;26(5):1153;Quach, H., Ritchie, D., Stewart, A.K., Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma (2010) Leukemia, 24 (1), pp. 22-32; Rychak, E., Mendy, D., Miller, K., Overcoming resistance: The use of pomalidomide (Pom) and dexamethasone (Dex) in re-sensitizing lenalidomide (Len)-resistant multiple myeloma (MM) cells (2011) Haematologica, 96 (S1), p. s126. , abstract. Abstract P-328; Lopez-Girona, A., Mendy, D., Ito, T., Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide (2012) Leukemia, 26 (11), pp. 2326-2335; Ocio, E.M., Fernández-Lázaro, D., San-Segundo, L., In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone (2015) Leukemia, 29 (3), pp. 705-714; Hideshima, T., Chauhan, D., Shima, Y., Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy (2000) Blood, 96 (9), pp. 2943-2950; Richardson, P.G., Siegel, D.S., Vij, R., Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: A randomized phase 2 study (2014) Blood, 123 (12), pp. 1826-1832; San Miguel, J., Weisel, K., Moreau, P., Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): A randomised, open-label, phase 3 trial (2013) Lancet Oncol, 14 (11), pp. 1055-1066; Dimopoulos, M.A., Weisel, K.C., Song, K.W., Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone (2015) Haematologica, 100 (10), pp. 1327-1333; (2015) Pomalyst (Pomalidomide) [Package Insert], , Summit, NJ. Celgene Corporation; (2015) Imnovid (Pomalidomide) [Summary of Product Characteristics], , Uxbridge, UK: Celgene Europe; Cockcroft, D.W., Gault, M.H., Prediction of creatinine clearance from serum creatinine (1976) Nephron, 16 (1), pp. 31-41; Durie, B.G.M., Harousseau, J.L., Miguel, J.S., International uniform response criteria for multiple myeloma (2006) Leukemia, 20 (9), pp. 1467-1473; Leleu, X., Attal, M., Arnulf, B., Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02 (2013) Blood, 121 (11), pp. 1968-1975; Lonial, S., Weiss, B.M., Usmani, S.Z., Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial (2016) Lancet, 387 (10027), pp. 1551-1560; Song, K.W., Dimopoulos, M.A., Weisel, K.C., Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma (2015) Haematologica, 100 (2), pp. e63-e67; Weisel, K., Dimopoulos, M., Song, K.W., Pomalidomide and low-dose dexamethasone improves health-related quality of life and prolongs time to worsening in relapsed/refractory patients with multiple myeloma enrolled in the MM-003 randomized phase III trial (2015) Clin Lymphoma Myeloma Leuk, 15 (9), pp. 519-530